Big Moving Stock chart patterns and volume.

Nasdaq: GOOG BIIB NFLX AMZN IBB TSLA ALXN SLXP AMGN COST BMRN WYNN AAPL VRTX CELG GMCR GILD SWKS SBUX
Nyse:
New Highs: ORLY LMT RCPT PANW CI WBC UNH SJM RH COL KRFT MSG TGT MKC RHT KSS AMBA CNC TJX KMX

The Hot Industries

Health Care Plans 3
Processed & Packaged Goods 2
Aerospace/Defense Products & Services 2

The Hot Sectors

Services 6
Consumer Goods 4
Healthcare 4

Social Buzz

CELG is headed higher?
Watchlist:

CELG Stock ChartSimilar Stocks: NVS EPZM OMED OTSK AMGN XLRN JNJ


CELG
Analyze

Sector:

Healthcare
Daily

Industry:

Biotechnology
Weekly

Employees:

5,100
Monthly

Website:

http://www.celgene.com

CELG Celgene Corporation

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases in the United States and internationally. The company’s commercial stage products include REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, as well as acute myeloid leukemia (AML); ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; and POMALYST/IMNOVID for the treatment of multiple myeloma. Its commercial stage products also comprise THALOMID for the patients with multiple myeloma and for the acute treatment of the cutaneous manifestations of erythema nodosum leprosum; ISTODAX to treat cutaneous T-cell lymphoma; and FOCALIN, FOCALIN XR, and RITALIN LA products. The company’s pre clinical and clinical stage products consist of OTEZLA for the treatment of psoriatic arthritis, psoriasis, and ankylosing spondylitis; CC-122 and CC-220 to treat hematological and solid tumor cancers; cellular therapies, such as PDA-001 and PDA-002 for Crohn’s and peripheral arterial diseases; CC-486, to treat MDS, AML, and solid tumors; Sotatercept and ACE-536 for the treatment of anemia in patients with rare blood disorders; CC-223 and CC-115 for lymphomas, hepatocellular, and prostate cancers; and CC-292 for the treatment of chronic lymphocytic leukemia and lymphomas. It has strategic drug discovery collaboration with Abide Therapeutics to enhance the treatment paradigm for patients with immune disorders. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.

favicon

Stock Market News for March 30, 2015 - Market News

30 Mar 2015, 8:10 amBenchmarks ended the last trading session of the week on a positive note after Fed Chair Janet Yellen said there was a possibility of a gradual hike in interest rates sometime this year
favicon

Stock Market Bulls Need to Step Up — or Else

27 Mar 2015, 6:45 am© Richard Drew/AP Photo Traders at their post on the floor of the New York Stock Exchange. Stocks bounced off a key support level on Thursday in an attempt to put an end to three consecutive days of losses.
favicon

Celgene (CELG) Stock Declines Today as Bubble Fears Grow

25 Mar 2015, 2:50 pmNEW YORK (TheStreet) -- Celgene shares closed trading down 4.21% to $117.01 on Wednesday as biotech stocks across the board were hit today as fears of an impending bubble in the sector rocked the NBI and smaller cap XBI ETFs today. The XBI -- SPDR S&P Biotech ETF fell 5% in trading today and has decreased 7% over the past five days, while the NBI ETF closed trading down 4.14% to $3,571.33.Fears ...
favicon

Stock Market News for March 24, 2015 - Market News

24 Mar 2015, 8:10 amMarkets ended its choppy session in the red yesterday as fluctuations in the value of the U.S. dollar weighed on investor sentiment
favicon

CELG Stock - Here's Why Celgene Is Worth Snapping Up

23 Mar 2015, 8:43 amCELG Stock - Here's Why Celgene Is Worth Snapping Up
favicon

Stock Market News for March 20, 2015 - Market News

20 Mar 2015, 8:10 amBenchmarks finished mostly lower on Thursday after stronger US dollar adversely affected oil and other commodity prices, dragging down energy and material stocks
favicon

Critical Alerts For Celgene, Cliffs Natural Resources, Cintas, Workday and Isis Pharmaceuticals Released By ...

19 Mar 2015, 7:46 amCHICAGO, March 19, 2015 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CELG, CLF, CTAS, WDAY and ISIS. To see what our analysts have discovered about a particular stock, read the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
favicon

Stock Market News for March 18, 2015 - Market News

18 Mar 2015, 8:10 amBenchmarks finished mostly lower on Tuesday as investors grew jittery ahead of FOMC’s statement regarding rate hike
favicon

Celgene could be the next celgene

9 Mar 2015, 6:15 amCelgene could be the next celgene
favicon

Celgene (CELG) Stock Gained Today on European Commission Approval of Revlimid

9 Mar 2015, 3:10 amNEW YORK (TheStreet) -- Celgene shares closed trading up 2.68% to $123.43 in trading on Friday, nearing its all time high of $124.60, after the European Commission approved the use of the company's Revlimid (lenalidomide) treatment for adult patients with previously untreated multiple myeloma who are transplant ineligible. The news comes one day after the company announced that the FDA expanded ...